Health-Related Quality of Life: Longitudinal Analysis From the Time of Breast Biopsy Into the Post-treatment Period

Michael J. Boivin1,2,3*, Alla Sikorskii1, Pamela Haan4, Stephanie S. Smith1, Laura L. Symonds5, Ravindra Khattree6, Bruno Giordani3, Adrian J. Blow7 and Janet R. Osuch4,8

1 Department of Psychiatry, Michigan State University, East Lansing, MI, United States, 2 Department of Neurology & Ophthalmology, Michigan State University, East Lansing, MI, United States, 3 Department of Psychiatry, University of Michigan, Ann Arbor, MI, United States, 4 Department of Surgery, Michigan State University, East Lansing, MI, United States, 5 Neuroscience Program, Michigan State University, East Lansing, MI, United States, 6 Department of Mathematics and Statistics, Oakland University, Rochester, MI, United States, 7 Department of Human Development and Family Studies, Michigan State University, East Lansing, MI, United States, 8 Department of Epidemiology, Michigan State University, East Lansing, MI, United States

Background: The physical, psychological, social, and spiritual quality of life (QoL) may be affected by breast cancer diagnosis and treatment, with mixed findings for psychological quality of life and cognitive ability performance. The present study aimed to evaluate QoL in women over 1 year from biopsy for a breast abnormality.

Methods: Self-reported measures of physical, psychological, social, and spiritual QoL were obtained after biopsy results but prior to treatment initiation (baseline), 4 and 12 months later. CogState computerized neuropsychological screening battery also provided an evaluation of psychological QoL. Three groups of women including those with benign biopsy results, those with malignancy treated with chemotherapy, and those with malignancy not treated with chemotherapy were compared at 4 and 12 months after adjusting for baseline to isolate the effects of treatment. Additional covariates included are age, level of education, and income.

Results: Benign biopsy results group included 72 women, whereas malignancy was found in 87 women of whom 33 were treated with chemotherapy and 54 without chemotherapy. At the time of diagnosis, women with cancer had worse psychological and social QoL but better spiritual QoL than those with benign biopsy results. Only CogState monitoring accuracy was worse for women with cancer compared with the controls at the time of biopsy results. After adjusting for QoL at baseline, women treated for cancer had worse physical and social QoL at 4 and 12 months later. Psychological well-being was worse for women with cancer at 4th month but improved at 1 year. No differences in cognition were found at 4 and 12 months when adjusted for baseline cognition and covariates.

Discussion: Breast cancer is a traumatic life event for women, affecting psychological and social QoL domains, yet increasing spiritual QoL. Later, cancer treatment worsens physical, psychological, and social QoL compared with those without cancer.
INTRODUCTION

Health-related quality of life (QoL) is a multi-dimensional concept divided into four domains, namely, physical, psychological, social, and spiritual (1, 2). Physical well-being captures physical functional ability, physical symptoms (e.g., pain, nausea), fertility, strength, and sleep. Psychological well-being includes symptoms of anxiety and depression, fear of recurrence, cognition, distress, enjoyment of life, and overall QoL perception. Social well-being reflects family distress, roles, and relationships, appearance, employment, isolation, and finances. Spiritual well-being captures the meaning of illness, religiosity, transcendence, hope, uncertainty, and positive changes. These domains are interrelated with each influencing the other while being affected by health conditions such as cancer and its treatment (3–5).

Breast cancer was the second leading cause of death among women in the United States until 2020 (6) and is expected to surpass heart disease in the next decade (7). A breast abnormality such as a lump begins a cycle of concern around biopsy and its results (8) even if the results indicate no malignancy (9). If malignancy is found, conventional medical care begins with surgery; however, some women may first undergo a course of chemotherapy to shrink the tumor before surgery (neoadjuvant therapy). For early-stage breast cancer, the most common surgery is the breast-conserving lumpectomy with sentinel node mapping. Following surgery, additional symptoms and concerns may include altered body image, pain, decreased arm range of motion, scars, brachial plexopathy, as well as, the knowledge of more advanced cancer with positive nodes. If adjuvant chemotherapy or targeted therapy is indicated, it is administered after surgery, may last for 6–12 months, and cause multiple symptoms, such as fatigue, nausea, and symptoms related to chemotherapy-induced menopause. Radiation therapy is administered after surgery either before or most often after adjuvant chemotherapy. If chemotherapy is not indicated, then 6 week radiation therapy follows surgery. Finally, hormonal therapy or trastuzumab is given for receptor-positive breast cancer for years after chemotherapy and/or radiation is complete (10–12).

For women with breast cancer, the evidence suggests that physical QoL is most affected by chemotherapy as opposed to other treatments (13, 14). More than 60% of women with breast cancer had clinically significant problems with fatigue and sleep (15). The poly-symptom experience of people with solid tumor cancers has been well-documented in the literature (16–19). Among people who have just finished chemotherapy, the median severity of pain and fatigue was 6 on a 0–10 scale (20), and sustained levels of post-treatment pain and fatigue, and peripheral neuropathy have been reported for people who have finished treatment for breast or other solid tumor cancers (21, 22).

Social support is of paramount importance during cancer treatment because it has been shown to reduce the risk of psychological distress and accompanying emotional support has been associated with better social and emotional well-being (23–29). The benefits of social and emotional support for the QoL of a cancer survivor are at least partly related to the reduction in negative appraisal and stressful response to illness (30–35). The spiritual domain of QoL has also been found to be positively related to psychological well-being and negatively related to symptom distress among breast cancer survivors (36, 37).

Psychological distress (depression and anxiety) is highly prevalent in breast cancer survivors and has negative consequences for multiple QoL domains (38–40). Depression occurs in up to 60% of cancer survivors across cancer sites and treatments (41). Between 35 and 65% report anxiety during treatment (42) and 45% experience both depression and anxiety (43, 44). Major depression occurs in approximately 16% of survivors, with subthreshold depressive disorders appearing in almost 22% during treatment (15). These prevalence rates are about 3 times higher than in the general population (45, 46). Psychological distress can interfere with cognitive functioning (e.g., memory, attention, and decision making) (47, 48) and motivation to enact self-management behaviors related to chronic diseases and their treatment (49–51).

The literature on cancer- and treatment-related changes in neurocognitive outcomes has mixed findings. Several studies, meta-analyses, and systematic reviews indicate small to moderate effect sizes for diminished cognitive functioning due to adjuvant chemotherapy (52–54). Another meta-analysis found consistent differences with normative scores only for visual memory, and small effect sizes in comparison to normative scores for executive function, information processing speed, and verbal memory (55). The most recent systematic review and meta-analysis supported elevated risk of neurocognitive dysfunction among women with breast cancer compared with controls, and women treated with chemotherapy compared with other modalities, although, strong statistical evidence was found in only three of 24 studies included in the meta-analysis (56). Mechanisms theorized to underpin cognitive changes have been proposed and included links between cytokines and epigenetic reprogramming (57), particularly with chemotherapy (58, 59). Boivin et al. (60) proposed that immunologic marker CD8+ was sensitive to a

**Conclusions:** These findings suggest that interventions to improve psychological QoL may be especially important at the time of cancer diagnosis, while interventions to improve physical well-being are the most needed during and following cancer treatment. Support to improve social QoL is needed from the time of diagnosis into post-treatment survivorship.

**Keywords:** breast cancer, quality of life, neuropsychology, emotional well-being, spiritual well-being
broad range of poorer QoL and neurocognitive functioning outcomes, especially in women undergoing chemotherapy (60). Finally, studies of neurocognitive functioning included various measures, from objective performance-based measures to self-report, which are often only weakly correlated and reflect potentially different constructs of cognitive ability (objective tests) vs. the functional effect of cognitive ability in everyday life (self-report) (61).

Understanding which QoL domains affected the most and when, beginning with time from cancer diagnosis and extending past the end of cancer treatment would inform supportive care interventions. This study was a case/control prospective observational cohort comparison (patients with breast cancer biopsy vs. matched control women with a benign biopsy diagnosis). As such, the present study aimed to compare the QoL outcomes in physical, psychological, social, and spiritual domains immediately after biopsy results and 4 and 12 months later among three groups of women with (a) benign biopsy results, (b) malignant tumors not treated with chemotherapy, and (c) malignant tumors treated with chemotherapy. We hypothesized that immediately after biopsy results, the groups with malignancy would have worse psychological QoL, including depression, anxiety, and cognition but better spiritual well-being; at 4 and 12 months, women with malignancy treated with chemotherapy will have worse physical, social, and psychological QoL compared with the other two groups.

**METHODS**

This research is based on longitudinal data on the QoL for a cohort of women recruited at the time of biopsy for a breast abnormality and followed for 1 year. The study was approved by the Institutional Review Board of Michigan State University and the affiliated oncology settings.

**Sample**

The sample included women who underwent a biopsy for a breast abnormality. Following a biopsy, a registered nurse recruiter or a radiological technologist who assisted with interventional breast biopsies approached potential participants for verbal consent to be contacted to learn more about the study. After obtaining the verbal consent, the name of the woman and telephone numbers were given to the nurse who was the project manager. The nurse called to the potential participant to explain the study, and if the woman agreed, informal consent was obtained. Following receipt of written consent and biopsy results, the project manager verified the inclusion and exclusion criteria.

All women had to be 18 years or older, able to speak and read English, and if subsequently diagnosed with breast cancer, treated with breast preservation therapy consisting of lumpectomy and whole-breast irradiation therapy. Exclusion criteria included the diagnosis of any cancer type within the last 5 years (excluding non-melanoma skin cancer), previous diagnosis of breast cancer, diagnosis of a major psychiatric disorder (e.g., bipolar disease and schizophrenia), deafness or blindness, and pregnancy at the time of recruitment. Further, exclusion criteria for the cancer cases included treatment with a mastectomy, involved margins histologically (indication of cancer spread beyond the identified abnormality), lack of planned breast irradiation at the tumor site, the start of systemic therapy (cancer therapy targeting entire body such as chemotherapy or hormonal therapy) prior to the first assessment, and receiving neo-adjuvant therapy (systemic therapy prior to breast cancer surgery).

Exclusion criteria for the control group included any non-solid breast mass, current biopsy results of atypical ductal or lobular hyperplasia or lobular carcinoma in situ (indication of no cancer but increased risk of developing cancer), history of lobular carcinoma in situ within the last 5 years, fine-needle aspiration biopsy as the only method of diagnosis, or any lesion not arising from the epithelial cells of the breast. Lobular carcinoma is not cancer, but the presence of those cells indicates an increased risk of cancer. Therefore, those women were excluded from the breast cancer group. Consenting women with benign biopsies were put into the control pool. As each cancer case was enrolled, a benign biopsy control was sought using the following probabilistic matching categories such as age (<40 years old, 40–59, and >60), education (some high school/high school diploma and some college/college degree), race (Caucasian and other), and menopause status (premenopausal and post-menopausal), so that the two groups would be demographically comparable to the extent possible. Women in the control pool not matched with any cancer cases within 4 months of consenting were removed from the pool. The first assessment (baseline) was conducted after biopsy results were known (7–10 days after biopsy), and before cancer treatment was initiated for those with malignant biopsy results, except when biopsy also served as surgery to remove the breast abnormality or tumor.

**Enrollment**

Of women with a breast cancer diagnosis approached for study enrollment, 87 were enrolled and underwent baseline assessment on the measures described below. Of these participants, two women were excluded: one due to death and the other lost to follow-up when unavailable for further contact, so 85 patients with breast cancer completed all the assessments for this study. The patients with breast cancer approached but were not enrolled, upon screening 139 were ineligible due to one of the exclusion criteria and 105 were eligible for enrollment but declined participation. This resulted in a total of 321 patients with breast cancer being approached for enrollment at the time of diagnosis, 87 of whom were enrolled and 244 who were not.

Seventy-two women with a benign (non-cancer) diagnosis for their breast abnormality biopsy agreed to participate and matched to one of our breast-cancer cases, so they were enrolled and completed the baseline assessment. Five of these women were lost to follow-up (two died, two moved away, and one we lost contact) so that 67 benign biopsy participants completed all the assessments. For the remaining women approached for study participation following benign breast biopsy, 153 agreed to participate and were entered into a pool where they could be matched to a breast cancer participant. However, after 16 weeks these women were removed out from the eligibility list for matching with patients with breast cancer and were not enrolled in the study. Another 313 benign biopsy women declined to
participate and 194 were deemed ineligible upon screening (e.g., previous diagnosis of breast cancer or medical history of prior breast abnormalities; self-reported diagnosis of clinical depression, anxiety disorder, or other psychiatric disorder).

**Measures**  
Questionnaires and tests described below were administered on a laptop computer during clinic appointments at baseline (following the results of the biopsy but before cancer treatment initiation for the women with breast cancer; at the next clinic appointment following biopsy for the benign biopsy participant), as well as 4 and 12 months later. Demographic characteristics including age, level of education, and income were collected at baseline only. The medical information included data on cancer and planned treatments. The second time point (4 months) corresponded to current or recently completed treatment in the chemotherapy group and completed radiation therapy in the non-chemotherapy malignant group, while at the third time point (12 months), cytotoxic chemotherapy was finished, although, hormonal therapy continued to be administered if prescribed. The measures covered the physical, psychological, social, and spiritual domains of the City of Hope Research (HR) QoL. Items referring to cancer were modified to refer to a breast abnormality for the benign control group.

Breast cancer-specific QoL was measured with the instrument developed by researchers at the City of Hope National Medical Center (HR QoL questionnaire). Evidence of validity and reliability has been reported (2, 62). Forty-six items are rated on a 0–10 rating scale and form 5 subscales: physical, psychological, fear, social, and spiritual. Higher scores reflect better QoL. Physical well-being subscale consists of 8 items evaluating fatigue, appetite changes, pain, sleep, weight gain, vaginal dryness/ menopausal symptoms, menstrual changes or fertility, and overall physical health. The psychological well-being subscale includes 17 items evaluating coping, happiness, control of life situations, concentration, appearance, single items on depression and anxiety, and items on distress from cancer diagnosis and treatment. Five-item fear subscale queried women on the extent of fear related to a future diagnostic test, second cancer, cancer recurrence, metastasis, and the degree that life is back to normal. The nine-item social well-being subscale evaluates concerns about the family, support from others, relationships, sexuality, employment, activities at home, isolation, financial burden, and concern about breast cancer in female relatives. The spiritual well-being subscale has seven items asking about religious activities, spiritual activities, changes in spiritual life and positive changes in life because of cancer, uncertainty about the future, sense of purpose/mission, and hope. Cronbach's alpha values for five subscales ranged from 0.70 to 0.90 in this study. This tool provided two measures of psychological QoL (psychological well-being and fear subscales), and one measure of each of the physical, social, and spiritual QoL. Additional in-depth measures reflecting the psychological QoL domain were administered to assess depression, anxiety, and cognition.

Depression was measured with the Patient Health Questionnaire (PHQ-9). The PHQ-9 has been reported to have good construct validity and reliability as a depression scale in the general population (63), recognizing both major depression and subthreshold depressive disorder (64). The PHQ brief scale consists of 9 items (PHQ-9) ranked from 0 to 3 and assesses the level of depressed mood over the previous 2 weeks. Total scores for the 9 items range from 0 to 27; the higher the score, the greater the degree of depression. Cronbach's alpha value was 0.84 at baseline.

Anxiety was measured using a short form of the State-Trait Anxiety Inventory (STAI) (65) state anxiety subscale scales (66). This measure consists of 5 items reflecting the state of (situational) anxiety. Trait anxiety measure was not administered because the focus of the study was on the effect of breast cancer diagnosis and treatment (situations) as opposed to a trait of personality. Participants ranked each item on a scale from 1 to 4. Total scores range between 5 and 20; the higher the score, the greater the degree of situational or state anxiety. Cronbach's alpha value was 0.85 at baseline.

CogState is a computerized cognitive assessment battery that uses stimuli consisting of common playing cards within a game-like context, making the assessment both less stressful and more engaging. Tests from CogState selected for this study assessed a wide range of cognitive ability domains including simple (Detection, DET) and choice (Identification, IDN) reaction time for attention, working memory (One Card Back, OCB), episodic learning, and memory (One Card Learning, OCL, and Continuous Paired-Associate Learning, CPAL), dual-task performance (Monitoring MON), and reasoning (Prediction, PRED). The entire battery took approximately 15–20 min to complete. Within Cogstate, equivalent stimuli are randomly chosen for each response trial, so repeated assessments can take place with minimum confounding from practice effects. CogState has good sensitivity and specificity in classifying mild cognitive impairment and has been shown the ability to detect the cognitive change in response to disease or its treatment (67–69). At the end of the CogState performance, items are a set of short questions where the respondent evaluates her performance on the test in terms of alertness, vigilance, memory, processing speed, and monitoring. In the present analyses, these responses are referred to as subjective metacognition self-ratings.

**Statistical Analyses**  
Descriptive statistics were obtained for each group such as those with benign biopsy results; those with malignant tumors not treated with chemotherapy; and those with malignant tumors treated with chemotherapy. The chi-square and ANOVA were used to compare the groups at baseline (87 breast cancer and 67 benign biopsy women). Linear mixed-effects (LME) models were employed to relate outcomes at 4 and 12 months and to relate outcomes at intake and covariates (age, level of education, and income). The LME modeling generalizes classical analysis of repeated measures and allows for data missing at random and structured covariance matrix. Even though, only 67 of the 72 benign biopsies enrolled women and 85 of the 87 enrolled women with breast cancer completed all the assessments, they could all still be included in the LME modeling analysis for the repeated measures because of how it allows for missing data. We
TABLE 1 | Demographic characteristics and outcomes at intake.

| Characteristic                  | Entire sample N = 159 | Benign group N = 72 | No Chemotherapy group N = 64 | Chemotherapy group N = 33 | P-value for group comparison |
|--------------------------------|-----------------------|---------------------|-----------------------------|---------------------------|-----------------------------|
|                                | N (%)                 | N (%)              | N (%)                       | N (%)                     |                             |
| Education                      |                       |                     |                             |                           |                             |
| High school or less            | 40 (25.16%)           | 15 (20.83%)         | 17 (31.48%)                 | 8 (24.24%)                | 0.34                        |
| Some college                   | 62 (38.99%)           | 29 (40.28%)         | 17 (31.48%)                 | 16 (48.48%)               |                             |
| College degree                 | 23 (14.47%)           | 11 (15.28%)         | 6 (11.11%)                  | 6 (18.18%)                |                             |
| Post-graduate work or degree   | 34 (21.38%)           | 17 (23.61%)         | 14 (25.93%)                 | 3 (9.09%)                 |                             |
| Income                         |                       |                     |                             |                           |                             |
| <$30,000                       | 46 (28.93%)           | 23 (31.94%)         | 11 (20.37%)                 | 12 (36.36%)               | 0.50                        |
| $30,000–$75,000                | 54 (33.97%)           | 24 (33.33%)         | 21 (38.99%)                 | 9 (27.27%)                |                             |
| More than $75,000              | 59 (37.11%)           | 25 (34.72%)         | 22 (40.74%)                 | 12 (36.36%)               |                             |
| Age                            |                       |                     |                             |                           |                             |
| Mean (St Dev)                  | 55.70 (8.72)          | 54.57 (8.61)        | 58.80 (8.32)                | 53.09 (8.41)              | <0.01                       |
| Physical QoL*                  | 65.70 (12.54)         | 67.53 (12.47)       | 65.99 (10.93)               | 61.20 (14.31)             | 0.02                        |
| Psychological QoL*             | 103.54 (18.95)        | 109.25 (15.03)      | 101.56 (19.49)              | 94.32 (21.79)             | <0.01                       |
| Fear*                          | 24.21 (11.82)         | 26.27 (11.15)       | 23.57 (11.88)               | 20.76 (12.56)             | 0.37                        |
| Social QoL*                    | 70.37 (14.06)         | 76.92 (10.46)       | 68.37 (13.33)               | 59.36 (14.51)             | <0.01                       |
| Spiritual QoL*                 | 48.19 (13.25)         | 44.76 (12.99)       | 50.53 (12.17)               | 51.84 (14.06)             | 0.01                        |
| Depression**                   | 4.87 (4.79)           | 4.03 (4.50)         | 4.74 (4.48)                 | 6.92 (5.40)               | 0.02                        |
| Anxiety**                      | 7.68 (2.93)           | 7.54 (2.91)         | 7.80 (2.88)                 | 7.79 (3.10)               | 0.87                        |
| Metacognitive score*           | 21.13 (4.56)          | 20.68 (4.28)        | 21.07 (5.34)                | 22.18 (3.63)              | 0.30                        |
| CogState identification time** | 2.78 (0.10)           | 2.76 (0.09)         | 2.79 (0.11)                 | 2.79 (0.10)               | 0.24                        |
| CogState detection time**      | 2.55 (0.12)           | 2.54 (0.12)         | 2.56 (0.12)                 | 2.56 (0.12)               | 0.47                        |
| CogState associate learning accuracy* | 0.84 (0.16)           | 0.86 (0.14)         | 0.85 (0.15)                 | 0.79 (0.21)               | 0.08                        |
| CogState spatial learning/working memory accuracy* | 0.53 (0.27)           | 0.59 (0.31)         | 0.50 (0.23)                 | 0.47 (0.22)               | 0.06                        |
| CogState monitoring accuracy*  | 1.10 (0.21)           | 1.15 (0.19)         | 1.11 (0.20)                 | 0.97 (0.23)               | <0.01                       |
| CogState non-verbal learning/memory accuracy (one card learning)* | 0.80 (0.13) | 0.81 (0.13) | 0.78 (0.11) | 0.79 (0.17) | 0.48 |
| CogState working memory accuracy (one card back)* | 1.31 (0.23) | 1.34 (0.24) | 1.31 (0.19) | 1.24 (0.25) | 0.11 |
| CogState reasoning/problem solving accuracy (prediction accuracy)* | 0.88 (0.12) | 0.90 (0.13) | 0.88 (0.12) | 0.86 (0.11) | 0.16 |

*Higher score indicates better outcome.  
**Higher score indicates worse outcome.  
Statistically significant probability (P) values for between-group differences are in bold.

also repeated the LME modeling analyses as shown in Table 2 including only the 67 benign biopsies and 85 women with breast cancer who completed all the assessments to see if any of the significant statistical findings would change however they did not so enrolled women were included in the LME modeling as shown in Table 2 using all available assessment data.

The essential parameters of interest in these models were associated with the group-by-time interaction. The least-square (LS) means for each group at 4 and 12 months were output from the LME models, and differences among LS means were tested. For the hypothesis about the physical QoL, City of Hope physical well-being scores were analyzed. For the comparison of psychological QoL, City of Hope psychological well-being and fear, and PHQ-9, STAI, and CogState were analyzed. For the comparison of social and spiritual QoL, the corresponding subscales of the City of Hope QoL tool were used. Because all
outcomes were defined a priori, no adjustments for multiple testing were made.

Sample Size and Power Considerations
The sample sizes for each group could not be set up a priori as women were enrolled prior to biopsy results and determination of treatment plan. Given the available sample sizes of 72, 54, and 33, the effect sizes (Cohen's $d$) detectable as statistically significant with the power of 0.80 in two-tailed tests at 0.05 level of significance in unadjusted pairwise group comparison were $d = 0.51$ and $0.59$ for the comparison of the benign group to two cancer groups, and $d = 0.63$ for the comparison between two cancer groups. In longitudinal analyses of two repeated measures with the adjustment for baseline, with a correlation of 0.4 between pairs of repeated measures, the detectable adjusted effect sizes were $d = 0.47, 0.55$, and 0.58, respectively.

RESULTS
The entire sample of 159 women included 87 women with histologically proven breast cancer defined as ductal carcinoma in situ or invasive ductal or invasive lobular carcinoma and 72 women with a non-proliferative epithelial cell breast biopsy performed within the previous 4 months. The demographic characteristics of the study sample and descriptive statistics of the outcomes at baseline for the entire sample and three groups of interest are summarized in Table 1. A total of five women (three in benign group, one in chemotherapy, and one in no chemotherapy group) dropped out between intake at 4 months, and an additional two women in the benign group were lost to follow-up between 4 and 12 months. Women with malignant biopsy results not treated with chemotherapy were older, whereas those treated with chemotherapy had worse psychological and social QoL at baseline, and worse scores on depression at baseline. The benign group had the lowest spirituality scores at baseline. Among CogState scores, only monitoring accuracy was worse in the group that later received chemotherapy (Table 1).

An Unadjusted Comparison of Study Groups at 4 Months Post-diagnosis on QoL
Figures 1, 2 display the box plot comparison of State-Trait Anxiety Inventory (STAI) total and PHQ-9 Depression inventory total for the benign biopsy (no breast cancer) group, no chemotherapy breast cancer, and chemotherapy breast cancer treatment groups at 4 months post-diagnosis (during treatment). The chemotherapy group had more anxiety and depression symptoms (higher median total scores) than the no-chemotherapy breast cancer group. Similarly, the no-chemotherapy group was poorer on these indicators than the benign biopsy (no breast cancer) group.

Using a bar graph with the SE extension for each group, Figure 3 depicts the unadjusted differences among our study group participants at 4 months post-diagnosis on the City of Hope QoL domains. Figure 4 is a box plot comparison for our comparison groups for cognitive performance tests comprising the computerized CogState neuropsychological cognitive performance screening battery. The chemotherapy treatment group was noticeably worse (lower scores) on all the QoL domains (Figure 3) and the CogState performance tests (Figure 4) compared with the no chemotherapy breast cancer and benign biopsy (no breast cancer) groups.

Longitudinal Analyses of Outcomes at 4 and 12 Months Adjusted for Baseline
Controlling for baseline scores allowed the longitudinal effects of treatment to be isolated over and above what could be attributed to the impact of initial diagnosis, with further adjustment for age, education, and income. Significant differences in outcomes as time progressed were found in physical, psychological, and social HR QoL as well as depression. The pattern of these differences was the same across multiple outcomes. The group with malignant tumors treated with chemotherapy had worse outcomes compared with the other two groups (Table 2).
Notably, over and above baseline values, no differences were found on spirituality, subjective (metacognition), or objective (CogState) measures of cognitive functioning. As for the within-group changes between 4 months and 1 year, the chemotherapy group had significant improvements in physical, psychological, and social well-being, and depression.

**DISCUSSION**

The comparison of groups with benign vs. malignant findings adds to the existing literature on the effects of breast cancer diagnosis and chemotherapy treatment on physical, psychological, social, and spiritual QoL. When comparing the benign biopsy (no breast cancer) group, no chemotherapy breast cancer, and chemotherapy breast cancer treatment groups, differences at the time of diagnosis were found on psychological, social, and spiritual QoL, favoring the benign group except for spirituality. Controlling for the QoL measures at the time of diagnosis and age, education, income, and chemotherapy group had more depressive symptoms than the no chemotherapy breast cancer and the control groups. We observed higher (better) QoL scores for the benign biopsy than the breast cancer groups on psychological, social, and physical QoL domains, respectively; and the chemotherapy treatment group had the worse scores for all these domains. However, the breast cancer groups were higher on spiritual QoL (more affirmation of positive spirituality items) than the benign (no breast cancer) group, even though, they were comparable at diagnosis. The fact that spiritual QoL can be higher for the participants with breast cancer during treatment while psychological and social QoL can be worse (compared with the benign biopsy group) is important to note. This is because this finding suggests that spirituality is not necessarily dependent on emotional well-being during treatment for a life-threatening disease for women diagnosed with breast cancer. Higher spirituality may buffer psychological distress resulting from cancer diagnosis (70).

These findings regarding depressive symptoms (part of psychological QoL) align with the literature indicating that breast cancer survivors have greater mental health problems than cancer-free controls (56, 71–73). The previous qualitative analysis

---

**FIGURE 3** | Hope Quality of Life (QoL) questionnaire total score bar graphs for the benign (breast lump autopsy), no-chemo (treatment for breast cancer), and chemo (treatment for breast cancer) groups. Higher scores mean better QoL for the psychological, social, spiritual, and physical domains respectively. The SE value for each group is capped above its bar.
FIGURE 4 | CogState computerized cognitive ability test score box plots for the benign (breast lump autopsy), no-chemo (treatment for breast cancer), and chemo (treatment for breast cancer) groups. Higher scores mean better cognitive performance on the battery of tests with playing cards. Box plots are presented for card detection accuracy, card identification accuracy, one-back card memory accuracy, card monitoring (prior card recognition learning) accuracy, card paired-associate learning accuracy, continuous paired-associate learning accuracy (CPAL), and card presentation pattern prediction accuracy. The SE value for each group is capped above its bar.

revealed that all women in this sample reported a difficult time pre-diagnosis (74). Because enrollment into the present study happened at the time of biopsy for a breast abnormality, we were able to discern the effect of the diagnosis vs. subsequent treatment. Greater depressive symptoms in the cancer groups were found at the time of diagnosis, but not 4 months and 1 year later when controlling for depression at the time of diagnosis. This finding is consistent with the literature on high (50%) prevalence of depressive symptoms shortly after cancer diagnosis and diminishing over the next year, while remaining higher than in the general population even years after cancer treatment completion (75–77). Even though, for most people with cancer depressive symptoms are not sufficiently severe to warrant a full clinical diagnosis of depression (78–81), but depressive symptomatology needs attention, as it has been suggested to be a predictor of better survival and reduced morbidity in several cancer populations (82).

Further, cancer treatment gives rise to multiple physical and emotional symptoms (19). The biological changes due to chemotherapy or other treatments and the resulting inflammatory processes may be responsible for the impairments in physical QoL (17, 83, 84), and these findings regarding physical QoL agree with the literature and contribute to the evidence that even a year after the cancer diagnosis, physical QoL remains worse for women with cancer compared to controls.

On the other hand, for some of the problems such as memory and concentration, chemotherapy may not be the cause, but rather, the stress of the diagnosis may be a significant contributor to early concerns expressed by women with cancer. The objective computer-based measures of cognition and attention showed no differences over time (85). It is possible that if patients report perceived problems with cognition (sometimes referred to as “chemo brain”), a broad evaluation may be needed to identify contributing issues related to all domains of QoL. The findings
## TABLE 2 | Least square (adjusted) means and SE of outcomes at 4 months and 1 year adjusted for intake, age, education, and income.

| Outcome                  | Benign group | No chemotherapy group | Chemotherapy group | $P$-value for group differences at 4 months | $P$-value for group differences at 1 year |
|--------------------------|--------------|-----------------------|--------------------|--------------------------------------------|------------------------------------------|
| **Physical QoL***         |              |                       |                    |                                            |                                          |
| 4 months                 | 67.01 (1.22) | 61.70 (1.41)          | 59.05 (1.81)       | $<$0.01                                    |                                          |
| 1 year                   | 68.29 (1.24) | 61.81 (1.41)          | 67.20 (1.81)***    | $<$0.01                                    |                                          |
| **Psychological QoL***    |              |                       |                    |                                            |                                          |
| 4 months                 | 106.02 (1.78) | 103.50 (2.03)          | 93.94 (2.61)***    | $<$0.01                                    |                                          |
| 1 year                   | 107.35 (1.80) | 106.50 (2.03)          | 104.08 (2.61)***   | 0.59                                       |                                          |
| **Fear**                 |              |                       |                    |                                            |                                          |
| 4 months                 | 26.62 (0.98) | 24.86 (1.11)          | 26.45 (1.43)       | 0.46                                       |                                          |
| 1 year                   | 27.96 (0.99) | 24.98 (1.11)          | 26.12 (1.45)       | 0.13                                       |                                          |
| **Social QoL***          |              |                       |                    |                                            |                                          |
| 4 months                 | 76.54 (1.22) | 71.28 (1.33)          | 61.62 (1.81)       | $<$0.01                                    |                                          |
| 1 year                   | 76.87 (1.23) | 71.80 (1.33)          | 69.85 (1.80)***    | $<$0.01                                    |                                          |
| **Spiritual QoL***       |              |                       |                    |                                            |                                          |
| 4 months                 | 46.74 (1.05) | 48.32 (1.20)          | 47.75 (1.54)       | 0.61                                       |                                          |
| 1 year                   | 49.11 (1.07) | 48.21 (1.19)          | 49.52 (1.54)       | 0.76                                       |                                          |
| **Depression***          |              |                       |                    |                                            |                                          |
| 4 months                 | 4.36 (0.47)  | 5.03 (0.55)           | 5.74 (0.55)        | 0.25                                       |                                          |
| 1 year                   | 4.14 (0.48)  | 4.57 (0.54)           | 3.11 (0.70)***     | 0.26                                       |                                          |
| **Anxiety***             |              |                       |                    |                                            |                                          |
| 4 months                 | 7.47 (0.33)  | 7.79 (0.38)           | 8.05 (0.49)        | 0.58                                       |                                          |
| 1 year                   | 7.44 (0.34)  | 7.11 (0.38)           | 7.71 (0.49)        | 0.62                                       |                                          |
| **Metacognitive score**  |              |                       |                    |                                            |                                          |
| 4 months                 | 22.37 (0.48) | 22.57 (0.55)          | 22.05 (0.70)       | 0.84                                       |                                          |
| 1 year                   | 21.11 (0.48) | 22.08 (0.55)          | 21.83 (0.70)       | 0.40                                       |                                          |
| **CogState identification time*** |            |                       |                    |                                            |                                          |
| 4 months                 | 2.78 (0.01)  | 2.77 (0.01)           | 2.78 (0.01)        | 0.64                                       |                                          |
| 1 year                   | 2.77 (0.01)  | 2.77 (0.01)           | 2.79 (0.01)        | 0.52                                       |                                          |
| **CogState detection time*** |            |                       |                    |                                            |                                          |
| 4 months                 | 2.54 (0.01)  | 2.57 (0.01)           | 2.58 (0.02)        | 0.17                                       |                                          |
| 1 year                   | 2.55 (0.01)  | 2.56 (0.01)           | 2.55 (0.02)        | 0.92                                       |                                          |
| **CogState associate learning accuracy*** |            |                       |                    |                                            |                                          |
| 4 months                 | 0.85 (0.02)  | 0.87 (0.02)           | 0.83 (0.03)        | 0.44                                       |                                          |
| 1 year                   | 0.84 (0.02)  | 0.82 (0.02)           | 0.80 (0.03)        | 0.44                                       |                                          |
| **CogState spatial learning/working memory accuracy*** |            |                       |                    |                                            |                                          |
| 4 months                 | 0.45 (0.03)  | 0.43 (0.03)           | 0.42 (0.04)        | 0.78                                       |                                          |
| 1 year                   | 0.47 (0.03)  | 0.45 (0.03)           | 0.44 (0.04)        | 0.77                                       |                                          |
| **CogState monitoring accuracy*** |            |                       |                    |                                            |                                          |
| 4 months                 | 1.08 (0.02)  | 1.04 (0.03)           | 1.08 (0.03)        | 0.46                                       |                                          |
| 1 year                   | 1.09 (0.03)  | 1.08 (0.03)           | 1.07 (0.04)        | 0.85                                       |                                          |
| **CogState non-verbal learning/memory accuracy (one card learning)** |            |                       |                    |                                            |                                          |
| 4 months                 | 0.82 (0.02)  | 0.79 (0.02)           | 0.81 (0.02)        | 0.51                                       |                                          |
| 1 year                   | 0.82 (0.02)  | 0.77 (0.02)           | 0.80 (0.03)        | 0.17                                       |                                          |
| **CogState working memory accuracy (one card back)** |            |                       |                    |                                            |                                          |
| 4 months                 | 1.33 (0.03)  | 1.31 (0.03)           | 1.25 (0.04)        | 0.38                                       |                                          |
| 1 year                   | 1.32 (0.03)  | 1.29 (0.04)           | 1.23 (0.05)        | 0.27                                       |                                          |
| **CogState reasoning/problem solving accuracy (prediction accuracy)** |            |                       |                    |                                            |                                          |
| 4 months                 | 0.89 (0.01)  | 0.86 (0.02)           | 0.86 (0.02)        | 0.49                                       |                                          |
| 1 year                   | 0.89 (0.02)  | 0.86 (0.02)           | 0.86 (0.02)        | 0.55                                       |                                          |

*Higher score indicates better outcome.
**Higher score indicates worse outcome.
***Significant change over time within group.
Statistically significant probability ($P$) values for between-group differences are in bold.
of this research are consistent with those obtained by Darby (86) in a study of 60 women (30 on chemotherapy and 30 controls), who found some problems in attention and learning prior to the start of chemotherapy, with only minor changes during and after the chemotherapy period (86). Neither cognitive test scores nor self-report of their cognitive performance of the women differed over the course of treatment or by the group; though initially, at the time of diagnosis before the initiation of treatment, the chemotherapy group demonstrated lower monitoring accuracy compared with the other two groups.

The effects of breast cancer disease and treatment, especially chemotherapy, on neuropsychological functioning have been examined in studies with patients with breast cancer over decades (87–89). The cognitive fatigue from the psychosocial stress associated with breast cancer disease and treatment may be largely responsible for diminished neuropsychological performance in people on active treatment (90) and years after finishing treatment (91). Finally, the use of immunological biomarkers during differing types of breast cancer treatment may help disentangle the effects of the disease itself and its treatment from the psychosocial stress, causing cognitive fatigue and diminished capacity (92, 93).

The limitations of the present study include relatively small sample size and unequal group sizes resulting from biopsy results and planned treatment. Women in the sample were also well-educated and the results may not generalize to those with lower education levels. Because the women in the sample were not randomly assigned to groups receiving and not receiving chemotherapy, any differences found between these groups in the outcome variables must be interpreted cautiously. Further, multiple clinical factors and preferences of women played a role in treatment decisions after a malignant biopsy result. We did not disentangle these factors because data on preferences of the women and medical record data were not uniformly available. Even if clinical data were available, extraneous confounding variables cannot be ruled due to the observational nature of this study.

CONCLUSIONS

These findings and those of others suggest that interventions to improve the emotional and cognitive components of QoL may be especially important at the time of cancer diagnosis. A threatening illness, such as breast cancer, can be conceptualized as a traumatic event in the life of a woman and her significant others. While the benign group experienced relief after diagnosis, the emotional problems intensified among those diagnosed with cancer. The cancer diagnosis experience evokes emotions and memories; and often these are negative, causing distress, which may affect multiple other QoL components. Supportive care interventions initiated at the time of diagnosis may be particularly impactful for psychological QoL, including depression and cognition.

DATA AVAILABILITY STATEMENT

The raw data supporting the conclusions of this article will be made available by the authors upon request, without undue reservation.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by Michigan State University’s Biomedical & Health Institutional Review Board (BIRB) application #05-1031S Breast Cancer SEQL (Spirituality, Emotional Well-being and Quality of Life) Project (IRRC#6059M) (PI: Michael J. Boivin). The patients/participants provided their written informed consent to participate in this study.

AUTHOR CONTRIBUTIONS

All authors listed have made a substantial, direct and intellectual contribution to the work, and approved it for publication.

FUNDING

This research was funded by the Templeton Advanced Research Program (TARP), sponsored by the Metanexus Institute on Religion and Science, with the generous support of the John Templeton Foundation. The funding sources had no role in study design, data collection, analysis, or interpretation.

ACKNOWLEDGMENTS

The authors wish to acknowledge Grace Boivin, Father Jake Foglio, Paul Swiecicki, and Kyle Walsh for their contributions. The research team thanks our dedicated participants who made this study possible.

REFERENCES

1. Ferrans CE, Zerwic JJ, Wilbur JE, Larson JL. Conceptual model of health-related quality of life. J Nurs Scholarsh. (2005) 37:336–42. doi: 10.1111/j.1547-5069.2005.00058.x
2. Ferrell B, Hassey-Dow K, Leigh S, Ly J, Gulasekaram P. Quality of life in long-term cancer survivors. Oncol Nurs Forum. (1995) 22:915–22.
3. Butt Z, Rosenbloom SK, Abernethy AP, Beaumont JL, Paul D, Hampton D, et al. Fatigue is the most important symptom for advanced cancer patients who have had chemotherapy. J Nat Comprehens Cancer Netw. (2008) 6:448–55. doi: 10.6004/jnccn.2008.0036
4. Grabsch B, Clarke DM, Love, A, DP M, Snyder RD, Bloch S. et al. Psychological morbidity and quality of life in women with advanced breast cancer: a cross-sectional survey. Palliat Support Care. (2006) 4:47–56. doi: 10.1017/S147895150600068
5. National Cancer Institute. About Cancer Survivorship Research: Survivorship Definitions (2009). Retrieved from http://cancercontrol.cancer.gov/ocs/definitions.html.
25. Hegelson VS, Cohen S. Social support and adjustment to cancer: reconciling descriptive, correlational, interventional research. Health Psychol. (1996) 15:135–48. doi: 10.1097/0000278-6133.13.2.135

26. Hogan BE, Linden W, Najarian B. Social support interventions: do they work? Clin Psychol Rev. (2002) 22:381–440. doi: 10.1016/S0272-7358(01)00102-7

27. Kozachik S, Wyatt GK, Given CW, Given B. Patterns of use of complementary therapies among cancer patients and their family caregivers. Cancer Nurs. (2006) 29:94–94. doi: 10.1097/00002820-200603000-00002

28. Wills TA, Shinar O. Measuring perceived and received social support. In Cohen S, Underwood LG, Gottlieb BH, editors. Social Support Measurement and Interventions: A Guide for Health and Social Scientists. New York, NY: Oxford University Press (2000). p. 86–135. doi: 10.1093/med/psych/9780195126709.003.0004

29. Wyatt G, Kurtz ME, Liken M. Breast cancer survivors: an exploration on quality of life issues. Cancer Nurs. (1993) 16:440–8. doi: 10.1097/00002820-199312000-00003

30. Given B, Given C, Sikorskii A, Jeon S, Sherwood P, Rahbar M. The impact of providing symptom management assistance on caregiver reaction: results of a randomized trial. J Pain Symptom Manage. (2006) 32:43–43. doi: 10.1016/j.jpainsymman.2005.05.019

31. Given B, Sikorskii A, Given C, You M. Effects of assisting cancer patients with symptom management on family members reports of burden and depression. Psychooncology. (2009) 18:570–1. doi: 10.1002/po.1594

32. Grov EK, Dahl AA, Moum T, Fossa SD. Anxiety, depression, and quality of life in caregivers of patients with cancer in late palliative phase. Ann Oncol. (2005) 16:1185–91. doi: 10.1093/annonc/mdl210

33. Meraviglia M. Effects of spirituality in breast cancer survivors. Oncol Nurs Forum. (2006) 33:E1–7. doi: 10.1188/06.ONF.E1-E7

34. Puchalski CM. Spirituality in the cancer trajectory. Ann Oncol. (2012) 23(Suppl. 3):49–55. doi: 10.1093/annonc/mds088

35. Caruso R, Giulia-Nanni M, Riba MB, Sabato S, Grassi L. Depressive spectrum disorders in cancer: diagnostic issues and intervention. A critical review. Curr Psychiatry Rep. (2017) 19:33. doi: 10.1007/s11920-017-0785-7

36. Fann JR, Thomas-Rich AM, Katon WJ, Cowley D, Pepping M, McGregor BA, et al. Major depression after breast cancer: a review of epidemiology and treatment. Gen Hosp Psychiatry. (2008) 30:112–26. doi: 10.1016/j.genhosppsych.2007.10.008

37. Luckett T, Goldstein D, Butow PN, Gembski V, Aldridge LJ, McGraw J, et al. Psychological morbidity and quality of life of ethnic minority patients with cancer: a systematic review and meta-analysis. Lancet Oncol. (2011) 12:440–50. doi: 10.1016/S1470-2045(11)70212-1

38. Veenstra DL, Delis DL, Goodwin GM, Hasegawa J, Shenkman B, Cohen RA, et al. Prevalence of depression, anxiety, and adjustment disorder in oncological, haematological, and palliative-care settings: a meta-analysis of 94 interview-based studies. Lancet Oncol. (2011) 12:160–74. doi: 10.1016/S1470-2045(11)7002-X

39. Van Uden-Kraan CF, Lissenberg-Witte BJ, Verdonck-de Leeuw IM. Body changes after cancer: female cancer patients’ perceived social support and their perspective on care. Support Care Cancer. (2019) 27:4299–306. doi: 10.1007/s00520-019-04729-w

40. Staiano AC, Woodley SD, Puchalski CM, Puchalski CM, van Uden-Kraan CF, Lissenberg-Witte BJ. Perceived social support and its impact on quality of life in early-stage breast cancer survivors and their supportive partners. J Telemed Telecare. (2013) 19:260–5. doi: 10.1177/1357633X13492289

41. Fann JR, Thomas-Rich AM, Katon WJ, Cowley D, Pepping M, McGregor BA, et al. Major depression after breast cancer: a review of epidemiology and treatment. Gen Hosp Psychiatry. (2008) 30:112–26. doi: 10.1016/j.genhosppsych.2007.10.008

42. Badger T, Segrin C, Pavvogel A, Lopez AM. The effect of psychosocial interventions delivered by telephone and videophone on quality of life in early-stage breast cancer survivors and their supportive partners. J Telemed Telecare. (2013) 19:260–5. doi: 10.1177/1357633X13492289

43. Fann JR, Thomas-Rich AM, Katon WJ, Cowley D, Pepping M, McGregor BA, et al. Major depression after breast cancer: a review of epidemiology and treatment. Gen Hosp Psychiatry. (2008) 30:112–26. doi: 10.1016/j.genhosppsych.2007.10.008

44. Puchalski CM. Spirituality in the cancer trajectory. Ann Oncol. (2012) 23(Suppl. 3):49–55. doi: 10.1093/annonc/mds088

45. Luckett T, Goldstein D, Butow PN, Gembski V, Aldridge LJ, McGraw J, et al. Psychological morbidity and quality of life of ethnic minority patients with cancer: a systematic review and meta-analysis. Lancet Oncol. (2011) 12:1240–8. doi: 10.1016/S1470-2045(11)70212-1
instrumentation validity in a cross-cultural study. *Qual Life Res.* (2008) 17:147–57. doi: 10.1007/s11136-007-9276-3

67. Ashing-Giwa KT, Tejero JS, Kim J, Padilla GV, Helleman G. Examining predictive models of HRQoL in a population-based, multiethnic sample of women with breast carcinoma. *Qual Life Res.* (2007) 16:413–28. doi: 10.1007/s11136-006-9198-4

68. Ahern E. Cognitive functioning in the first-episode of major depressive disorder: a systematic review and meta-analysis. *Neuropsychology.* (2017) 31:52–72. doi: 10.1037/neu0000319

69. Greer J, Mario J, Trager L. Anxiety disorders. In Holland BW, Butow JC, Jacobsen PB, Lorschal MJ, McCorkle R, editors. *Psycho-Oncology.* New York, NY: Oxford (2016). p. 296–303.

70. Wagner GJ, Ghosh-Dastidar B, Robinson E, Ngo VK, Glick P, Mukasa B, et al. Effects of depression alleviation on ART adherence and HIV clinic attendance in Uganda, and the mediating roles of self-efficacy and motivation. *AIDS Behav.* (2016) 21:1655–64. doi: 10.1007/s10461-016-1500-0

71. Wagner GJ, Slaughther M, Ghosh-Dastidar B. Depression at treatment initiation predicts HIV antiretroviral adherence in Uganda. *J Int Assoc Provid AIDS Care.* (2017) 16:161–7. doi: 10.1177/1545109716677121

72. Anderson-Hanley C, Sherman ML, Riggs R, Agocha V, Compas B. Neuropsychological effects of treatments for adults with cancer: a meta-analysis and review of the literature. *J Int Neuropsychol.** (2003) 9:967–82. doi: 10.1017/S1355617703970019

73. Janelins MC, Kleser SR, Ahles TA, Morrow GR. Prevalence, mechanisms, and management of cancer-related cognitive impairment. *Int Rev Psychiatry.* (2014) 26:102–13. doi: 10.3109/09540261.2013.864260

74. Stewart A, Collins B, Parkinson M, Tomiak E. A meta-analysis of studies of the effects of cancer chemotherapy on various domains of cognitive function. *Cancer.* (2005) 104:2222–33. doi: 10.1002/cncr.21469

75. Carreira H, Williams R, Muller M, Harewood R, Stanway S, Bhaskaran K. Associations between breast cancer survivorship and adverse mental health outcomes: a systematic review. *J Natl Cancer Inst.* (2018) 110:1311–27. doi: 10.1093/jnci/djy177

76. Wang XM, Walitt B, Saligan L, Tiwari AF, Cheung CW, Zhang ZJ. Chemobrain: a critical review and causal hypothesis of link between cytokines and epigenetic reprogramming associated with chemotherapy. *Cytokine.* (2015) 72:86–96. doi: 10.1016/j.cyt.2014.12.006

77. Ahles TA, Saykin AJ. Candidate mechanisms for chemotherapy-induced cognitive changes. *Nat Rev Cancer.* (2007) 7:192–201. doi: 10.1038/nrc2073

78. Kovachuk A, Kolb B. Chemobrain: from discerning mechanisms to lifting the brain fog: An aging connection. *Cell Cycle.* (2017) 16:1345–9. doi: 10.1002/cccl.201734022

79. Boivin MJ, Aaron GP, Felt NG, Shamoun L. Preliminary study on the effects of computerized cognitive assessment tests on quality of life and neuropsychological performance. *BMC Womens Health.* (2020) 20:109. doi: 10.1186/s12905-020-00971-4

80. Costa DSJ, Fardell JE. Why are objective and perceived cognitive function weakly correlated in patients with cancer? *J Clin Oncol.* (2019) 37:1154–8. doi: 10.1200/JCO.18.02363

81. Boivin MJ, Aaron GP, Felt NG, Shamoun L. Preliminary study on the effects of treatment for breast cancer: immunological markers as they relate to quality of life and neuropsychological performance. *BMC Womens Health.* (2020) 20:109. doi: 10.1186/s12905-020-00971-4

82. Costa DSJ, Fardell JE. Why are objective and perceived cognitive function weakly correlated in patients with cancer? *J Clin Oncol.* (2019) 37:1154–8. doi: 10.1200/JCO.18.02363

83. Ferrell B, Dow K, Grant M. Measurement of the quality of life in cancer survivors. *Qual Life Res.* (1995) 4:523–31. doi: 10.1007/BF00634747

84. Kroenke K, Spitzer R, Williams J. The PHQ-9: validity of a brief depression severity measure. *J Gen Intern Med.* (2001) 16:606–13. doi: 10.1046/j.1525-1497.2001.0016009606.x

85. Martin A, Rief W, Klapproth E. Validity of the brief Patient Health Questionnaire Mood Scale (PHQ-9) in the general population. *Gen Hosp Psychiatry.* (2006) 28:71–7. doi: 10.1016/j.genhosppsych.2005.07.003

86. Spielberger CD, Gorsuch RL, Lushene R, Vagg PR, Jacobs GA. *Manual for the State-Trait Anxiety Inventory (Form Y).* Palo Alto: Mind Garden, Inc. (1983).
86. Darby D. Chemotherapy may not affect memory in breast cancer patients. *Paper presented at the American Academy of Neurology 60th Annual Meeting* (2008). Available online at: https://www.aan.com/PressRoom/Home/PressRelease/590 (accessed April 26, 2020).

87. Lange M, Heutte N, Rigal O, Noal S, Kurtz JE, Levy C, et al. Decline in cognitive function in older adults with early-stage breast cancer after adjuvant treatment. *Oncologist.* (2016) 21:1337–48. doi: 10.1634/theoncologist.2016-0014

88. Ng T, Phye XY, Yeo HL, Shwe M, Gan YX, Ng R, et al. Impact of adjuvant anthracycline-based and taxane-based chemotherapy on plasma VEGF levels and cognitive function in breast cancer patients: a longitudinal study. *Clin Breast Cancer.* (2018) 18:e927–37. doi: 10.1016/j.clbc.2018.03.016

89. Yao C, Bernstein LJ, Rich JB. Executive functioning impairment in women treated with chemotherapy for breast cancer: a systematic review. *Breast Cancer Res Treat.* (2017) 166:15–28. doi: 10.1007/s10549-017-4376-4

90. Miura K, Ando S, Imai T. The association of cognitive fatigue with menopause, depressive symptoms, and quality of life in ambulatory breast cancer patients. *Breast Cancer.* (2016) 23:407–14. doi: 10.1007/s12282-014-0578-3

91. Firouzbakht M, Hajian-Tilaki K, Moslemi D. Analysis of quality of life in breast cancer survivors using structural equation modelling: the role of spirituality, social support and psychological well-being. *Int Health.* (2020) 12:564. doi: 10.1093/inthealth/ihaa013

92. Hermelin K, Buhner M, Sckopke P, Neufeld F, Kaste J, Voigt V, et al. Chemotherapy and post-traumatic stress in the causation of cognitive dysfunction in breast cancer patients. *J Natl Cancer Inst.* (2017) 109. doi: 10.1093/jnci/djx057

93. Lindner OC, Phillips B, McCabe MG, Mayes A, Wearden A, Varese F, et al. A meta-analysis of cognitive impairment following adult cancer chemotherapy. *Neuropsychology.* (2014) 28:726–40. doi: 10.1037/neu000064

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher's Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Boivin, Sikorski, Haan, Smith, Symonds, Khattree, Giordani, Blow and Osuch. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.